Thank you for sharing!

Your article was successfully shared with the contacts you provided.
When Sanofi-Synth�labo hired Laurent Cohen-Tanugi as its new senior vice president for legal affairs and GC in January, the Paris-based pharmaceutical giant got both a lawyer and a man of letters. In addition to 20 years of experience in the Paris office of Cleary, Gottlieb, Steen & Hamilton, the 46-year-old has had an accomplished career as a public intellectual. Cohen-Tanugi has published six books on European affairs and transatlantic relations, plus dozens of columns for French newspapers. His most recent book, An Alliance at Risk: The United States and Europe Since September 11, was translated into English and published by Johns Hopkins University Press in September. How did a Cleary, Gottlieb partner find time to become such a Renaissance man? “I write in the evenings and weekends and on vacation,” Cohen-Tanugi explains. Plus, he says: “I write easily.” His immersion in intellectual pursuits began early. Cohen-Tanugi graduated from one of France’s most selective liberal arts programs, at the University of Paris, before beginning his legal studies, which included earning a master of laws degree from Harvard Law School. Cohen-Tanugi says he still draws on the lessons he learned during the three years he spent reading Marcel Proust, Jorge Luis Borges, and other intellectual giants. “Literature studies help you know how to write well, and also how to read,” he says. And while a background in literature may not be relevant to the pharmaceutical industry, the lawyer-writer says he is excited to be in-house. A corporate generalist by choice, Cohen-Tanugi says he had become increasingly frustrated by his firm’s pressure to specialize. The onslaught of new responsibilities at Sanofi-Synth�labo, France’s second-largest drugmaker, will cut into his writing time. Between heading a 100-lawyer department and serving on the company’s executive team, the GC says he may need to put his next book on hold. But Cohen-Tanugi is hardly ready to abandon his intellectual pursuits. “I’m definitely expecting to continue writing and being in the public debate,” he says. For now, though, the only text Cohen-Tanugi may have time for is Sanofi-Synth�labo’s annual report.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]

Reprints & Licensing
Mentioned in a Law.com story?

License our industry-leading legal content to extend your thought leadership and build your brand.


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.